Axil Capital Partners

AIBIOS has designed and developed a series of novel small molecules which modulate both the innate (macrophages) and adaptive immune system to treat therapeutic indications of Gastroenterology, Respiratory, and Neurological diseases.

Suono Bio, Inc. is focused on developing a novel platform technology for the rapid and localized delivery of therapeutic products, specifically targeting the gastrointestinal (GI) tract. Incorporated in 2016 and based in Medford, Massachusetts, the company aims to facilitate the administration of small molecules, proteins, vaccines, and nucleic acids without the need for encapsulation. Preclinical studies have shown the platform's effectiveness in delivering various therapeutics both locally and systemically, which supports its potential for treating inflammatory-mediated diseases. This innovative approach may offer significant advancements in therapeutic delivery, enhancing patient recovery from gastrointestinal conditions.

TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates. Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.

Jolly Good Inc. is a Japan-based company that specializes in developing virtual reality (VR) technology for various professional applications, particularly in the fields of television, film, and medicine. The company's flagship mobile application, GuruVR, offers 360° content tailored for media professionals. In addition to its VR solutions, Jolly Good also provides consulting and planning services to enhance the effective implementation of its technology. The company has expanded its expertise to include high-precision augmented reality (AR) and VR systems designed for medical training and long-term care, as well as social skill training for individuals with developmental disabilities. Through its innovative approaches, Jolly Good aims to optimize treatment outcomes and improve training processes within the medical community and related industries.

United Immunity is a research, development, manufacture and sale of pharmaceuticals, mainly for cancer immunotherapy.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.

Jolly Good Inc. is a Japan-based company that specializes in developing virtual reality (VR) technology for various professional applications, particularly in the fields of television, film, and medicine. The company's flagship mobile application, GuruVR, offers 360° content tailored for media professionals. In addition to its VR solutions, Jolly Good also provides consulting and planning services to enhance the effective implementation of its technology. The company has expanded its expertise to include high-precision augmented reality (AR) and VR systems designed for medical training and long-term care, as well as social skill training for individuals with developmental disabilities. Through its innovative approaches, Jolly Good aims to optimize treatment outcomes and improve training processes within the medical community and related industries.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

United Immunity is a research, development, manufacture and sale of pharmaceuticals, mainly for cancer immunotherapy.

TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates. Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.

Himuka AM Pharma is a pharmaceutical company based in Miyazaki City, Japan, founded in February 2017. The company focuses on the research, development, and discovery of new drug seeds aimed at enhancing adrenomedullin, a peptide involved in various physiological processes. Through its innovative approach, Himuka AM Pharma seeks to contribute to advancements in medical treatments and improve health outcomes.